Scarica l'app Stockscreener
230.93
1.17%
3.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $240.93, Implies 6% Upside - TradingView
Quest Diagnostics stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Trending Industry Today: Quest Diagnostics Leads Gains In CRO Stocks - Moomoo
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Diagnostics Inc (DGX) Shares Surge 8.6% -- What GF Score o - GuruFocus
Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance
Quest Continues to Build on Its Hospital Lab Collaborations - Morningstar
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $229.6, Implies 9% Upside - TradingView
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics 2026: Revenue $3.04B, EPS $2.84— 10-Q Summary - TradingView
Quest Diagnostics (NYSE: DGX) lifts Q2 EPS to $2.84 on 10% revenue growth - Stock Titan
Quest Diagnostics Q2 Earnings Call Highlights - Yahoo Finance
Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street - StocksToTrade
Quest Diagnostics Stock Hits 52-Week HighHere's WhyQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics raises annual forecast on testing demand - Reuters
Quest Diagnostics Q2 2026 Results: Revenue Surges 10%, EPS Up 19%, Full-Year Guidance Raised - Minichart
Quest Diagnostics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday - Benzinga
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - marketscreener.com
Quest Diagnostics stock hits all-time high at 227.31 USD By Investing.com - Investing.com Canada
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call - Benzinga
DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised - TradingView
Quest Diagnostics Incorporated (DGX) Q2 FY2026 earnings call transcript - Yahoo Finance
Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars - Yahoo Finance
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics raises full-year guidance after Q2 revenue rises 10.2% - scanx.trade
Is Quest Diagnostics Inc (DGX) Overvalued After Q2 Earnings Beat - GuruFocus
Quest Diagnostics (NYSE:DGX) Surges After Crushing Q2 Estimates and Raising Guidance - ChartMill
Quest Diagnostics Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
Quest Diagnostics stock rises 5% on strong Q2 beat, raised guidance - Investing.com Canada
(DGX) Quest Diagnostics Expects Full Year 2026 Revenue Range $11.95B$12.05B, vs. FactSet Est of $11.85B - marketscreener.com
Earnings Flash (DGX) Quest Diagnostics Incorporated Reports Q2 Revenue $3.04B, vs. FactSet Est of $2.97B - marketscreener.com
Earnings Flash (DGX) Quest Diagnostics Incorporated Posts Q2 Adjusted EPS $3.12 per Share, vs. FactSet Est of $2.82 - marketscreener.com
Quest Diagnostics (DGX) Earnings Surpass Estimates with Raised FY Adj EPS Forecast - Smartkarma
Quest Diagnostics: Q2 Earnings Snapshot - Yahoo Finance
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 - PR Newswire
Quest Diagnostics earnings on deck as testing growth accelerates By Investing.com - Investing.com Canada
Quest Diagnostics stock trades steadily as recent earnings and data volumes shape outlook - Ad-hoc-news.de
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Quest Diagnostics stock trades steadily as investors weigh recent revenue growth and dividend income - Ad-hoc-news.de
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics | SCHEDULE 13G/A: Others - Moomoo
Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends - Ad-hoc-news.de
Is Quest Diagnostics Inc (DGX) Overvalued After 3.8% Rally? GF V - GuruFocus
A 9-Day Losing Streak Has Quest Diagnostics Stock Down 6.2% - Trefis
Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth - Ad-hoc-news.de
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating - marketscreener.com
Quest Diagnostics Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since September 2001 -- Data Talk - Moomoo
A4ET8Q Bond Profile — Key Metrics - TradingView
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus - Zacks Investment Research
A28XES Bond Risk Profile - TradingView
US74834LBB53 Bond Coupon Profile — Rate & Payments - TradingView
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD) - The Globe and Mail
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $245 - Moomoo
Baird Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $236 - Moomoo
Quest Diagnostics stock holds steady as diagnostics demand supports long-term growth - ad-hoc-news.de
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
Quest Diagnostics (DGX) Proxy filing Summary - Quartr
0.47%
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):